Harpreet Singth

Chief Medical Officer, Precision for Medicine

Dr. Harpreet Singh serves as Chief Medical Officer of Precision for Medicine, a global leader in biomarker-driven clinical research and development. Dr. Singh was previously an Oncology Division Director at the U.S. Food and Drug Administration (FDA) and is responsible for medical strategy and oversight at Precision. She is an experienced leader with a demonstrated track record in building high performing cross functioning teams, developing, and maintaining excellent working relationships with colleagues in academia, industry, and international regulatory bodies. Motivated by a desire to accelerate breakthrough treatments in oncology and rare disease, Dr. Singh has a multi-dimensional understanding of drug development along with deep experience as a medical oncologist, having trained at the National Cancer Institute and the University of Southern California Keck School of Medicine. Dr. Singh maintains an active public presence as a thought leader for important issues facing the life sciences industry.

Debs Phippard

Chief Scientific Officer, Precision for Medicine

Dr. Deborah Phippard is a seasoned biotechnology leader with over 30 years of experience in biomarker-driven clinical trial design and drug development. She has led programs for pharmaceutical and diagnostics companies as well as the NIH. Prior to joining Precision for Medicine, she held leadership roles at Roche and the Immune Tolerance Network, where she directed global biomarker and discovery research. Her scientific contributions include the discovery of pharmacodynamic biomarkers and novel targets for inflammatory diseases. Dr. Phippard earned her PhD in Molecular & Cell Biology from the University of London and continues to drive innovation in translational research and precision oncology.

Hannah Deresiewicz

EVP, Managing Director, Investor Relations & External Communications, Precision AQ

Hannah Deresiewicz is a strategic communications expert, known for her dynamic approach to biotech investor relations. With extensive experience supporting companies across phases of development and therapeutic areas – commercial launches, IPOs, and mergers, she excels at crafting compelling narratives that resonate with investors and stakeholders. Her leadership at Precision AQ is defined by authenticity, ambition, and approachability, helping life sciences companies elevate their visibility and engagement across capital markets.

Greg Gregory

EVP, Partner, Precision AQ

Dr. Greg Gregory is a life sciences veteran with deep expertise in pricing, market access, and commercialization strategy. With a PhD in Immunology & Molecular Pathogenesis and postdoctoral fellowship in hematology-oncology and the Children’s Hospital of Philadelphia, he has spent decades advising both emerging biotech firms and global pharmaceutical companies through pivotal launches and pricing decisions that unlock long‑term value. His specialization in rare diseases, orphan drugs, and vaccines has made him a trusted partner in launching transformative therapies. At Precision AQ, Dr. Gregory leads strategic consulting programs focused on access strategy, launch excellence, and evidence‑led value creation.

Dan Cummings

Chief Commercial Officer, Precision AQ

Dan Cummings is a seasoned commercial operator and strategist with over a decade of experience in business development, marketing, sales operations, and market access consulting. Before joining Precision AQ, he held senior leadership roles at Envision Pharma Group, Capsule Pharmacy, and Syneos Health. His career began in market access consulting at The Dedham Group and Decision Resources Group. At Precision AQ, Dan leads its commercial and go-to-market functions, connecting biopharmaceutical companies to Precision AQ’s people, perspectives, and proprietary data to bring life-changing therapies to market via precise commercialization. His customer-first mindset and cross-functional expertise are instrumental in driving growth and innovation across the organization.

moderator

Surani Fernando

Healthcare journalist, writer & podcaster

Surani Fernando is a seasoned healthcare journalist and editor with over 13 years experience covering the biopharma industry. A Sydney native, she started her investigative journalism career in London covering clinical trials, M&A and financing deals for BioPharm Insight, later moving to New York to continue her work as an enterprise journalist and editorial leader for GlobalData and Reorg. She is now based in Madrid working as a freelance journalist, consultant writer and podcast producer. In November 2023, she launched the Raising Biotech podcast.